Among them, we chose the E3 Ubiquitin Protein Ligase MDM2, a well‐known oncogene as a potential therapeutic target for wtTP53‐RTK NSCLC for further study. This evidence concerns the gene UBE2E3 and non-small cell lung carcinoma.